Lymphoplasmacytic lymphoma or multiple myeloma: immunoglobulins may lead to misdiagnosis

Debus, Jérôme; Lemaire, Pierre; Alani, Mustafa; Farhi, Jonathan; Rose, Johann; Cussac, Vincent; Defasque, Sabine; Denizon, Nathalie; Ghnaya, Habib; Besançon-Bergelin, Anne; Laribi, Kamel; Pineau-Vincent, Fabienne

doi:10.1684/abc.2018.1357

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It was found that the symptoms of OMG patients improved to varying degrees after the application of immunoglobulin, and most patients began to improve their symptoms within 45 d of starting treatment, and the efficacy lasted for about 2 months [17]. In addition, intravenous immunoglobulin does not require placement of a central venous cannula and is well tolerated, with only minimal and mild side effects, making it safer and more reliable for elderly patients or patients with hypotension and neurological disorders [18]. The relationship between complement and MG is also receiving increasing attention, as it plays an important role in the pathogenesis of OMG, with C3 and C4 forming a membrane attack complex deposited at the NMJ, thereby disrupting AChR transmission [19].…”

Section: Discussionmentioning

confidence: 99%

Clinical Efficacy of Immunoglobulin Combined with Glucocorticoids in the Treatment of Oculomotor Myasthenia Gravis in Children and the Effect on Serum Immunity

Fan

Yang

Zhang

et al. 2022

Computational and Mathematical Methods in Medicine

View full text Add to dashboard Cite

To investigate the effects of treatment with immunoglobulin on clinical outcomes and immune function in children with oculomotor myasthenia gravis. The clinical data of 100 pediatric patients with oculomotor myasthenia gravis treated in our hospital from January 2019 to December 2021 were selected as the subjects of this retrospective study and divided into a comparison group and a treatment group according to the different treatment methods. The comparison group was treated with glucocorticoids, and the treatment group was treated with immunoglobulin on the basis of the comparison group. The differences in the serum indexes, the effects of immune function, and the clinical efficacy of the two groups were observed and compared. It was found the comparison of immunoglobulin G (IgG), immunoglobulin A (IgA), and immunoglobulin M (IgM) after treatment was significantly different and lower in the treatment group than in the comparison group; the comparison of CD4+, CD3+, CD4+/CD8+, and NK cells after treatment was significantly different and higher in the treatment group than in the comparison group. The effective rate of 98.00% in the treatment group was significantly higher than that of 76.00% in the comparison group, and the difference was statistically significant. The clinical efficacy of the two groups showed that the fever, cough, sputum, myasthenia gravis crisis, and gastrointestinal reactions in the treatment group were significantly lower than those in the comparison group. The study indicates that comparative study of children with oculomotor myasthenia gravis treated with immunoglobulin combined with glucocorticoids is more effective, effectively improving the immune level of patients and reducing adverse reactions.

show abstract

Section: Discussionmentioning

confidence: 99%